Comparison of alteplase and urokinase in thrombolytic therapy for central retinal artery occlusion

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500105150

Enrollment

Unknown

Registered

2025-06-30

Start date

2025-07-01

Completion date

Unknown

Last updated

2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central retinal artery occlusion

Interventions

Alteplase group:Alteplase thrombolysis

Urokinase group:Urokinase thrombolytic therapy

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with clinical diagnosis of central retinal artery occlusion

Exclusion criteria

Exclusion criteria: 1. History of panretinal laser photocoagulation or anti-vascular endothelial growth factor therapy, and other types of intraocular surgery 2. History of ocular trauma 3. With other retinal/choroidal diseases, age-related macular degeneration, vitreoretinal traction, epiretinal membrane, macular hole or uveitis, etc. 4. Poor WSS-OCTA image quality in both eyes and poor patient compliance

Design outcomes

Primary

Measure	Time frame
Vision;Retinal thickness;	—

Secondary

Measure	Time frame
Retinal blood flow;	—

Countries

China

Contacts

Public ContactHuadong Lou

Qingdao Eighth People’s Hospital

qdbylhd@163.com+86 157 5329 5360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026